Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects ...
Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia ...
In the small, single-arm trial of 21 patients with a genetically confirmed PH1 diagnosis, treatment with lumasiran yielded a 33.33% (95% CI -15.16 to 81.82) least-square mean reductions in plasma ...
Experimental studies and small clinical trials have suggested that treatment with intranasal oxytocin may reduce social impairment in persons with autism spectrum disorder. Oxytocin has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback